Drug Approval | July 22, 2024
Briefs: Zydus Lifesciences and Divi's Laboratories
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
The proposed facility is expected to be operational around January, 2027
The delegation's visit covered a wide range of topics
Divis Laboratories has reported total income of Rs. 2,197 crores during the period ended June 30, 2024
Divi's Laboratories Limited has reported total income of Rs. 1995 crores during the period ended September 30, 2023
Divi's Laboratories Limited has reported consolidated financial results for the period ended September 30, 2021.
Subscribe To Our Newsletter & Stay Updated
